An Improved Model for Disease Progression in Patients From the Alzheimer's Disease Neuroimaging Initiative
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The objective of this analysis was to develop a semi‐mechanistic nonlinear disease progression model using an expanded set of covariates that captures the longitudinal change of Alzheimer's Disease Assessment Scale (ADAS‐cog) scores from the Alzheimer's Disease Neuroimaging Initiative study that consisted of 191 Alzheimer disease patients who were followed for 2 years. The model describes the rate of progression and baseline disease severity as a function of influential covariates. The covariates that were tested fell into 4 categories: (1) imaging volumetric measures, (2) serum biomarkers, (3) demographic and genetic factors, and (4) baseline cognitive tests. Covariates found to affect baseline disease status were years since disease onset, hippocampal volume, and ventricular volume. Disease progression rate in the model was influenced by age, total cholesterol, APOE ε4 genotype, Trail Making Test (part B) score, and current levels of impairment as measured by ADAS‐cog. Rate of progression was slower for mild and severe Alzheimer patients compared with moderate Alzheimer patients who exhibited faster rates of deterioration. In conclusion, this model describes disease progression in Alzheimer patients using novel covariates that are important for understanding the worsening of ADAS‐cog scores over time and may be useful in the future for optimizing study designs through clinical trial simulations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's Disease Neuroimaging Initiative (ADNI)
Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Shaw, L. M., Toga, A. W., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181cb3e25 · Cited by 2,572
Apolipoprotein E polymorphism and Alzheimer's disease
Poirier, J., Bertrand, P., Poirier, J., Kogan, S., Gauthier, S., Poirier, J., Gauthier, S., Davignon, J., Bouthillier, D., & Davignon, J. (1993) · The Lancet · doi:10.1016/0140-6736(93)91705-q · Cited by 1,108
Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People
De Meyer, G. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.179 · Cited by 462 · cited 1×
“In addition, recent reports have shown that elderly normal controls and patients with MCI in ADNI show bimodal distributions with respect to their biomarker profiles and disease progression characteristics (ie, converters vs nonconverters).(8) To accommodate bimodal distributions, disease progression analysis using mi…”
BackgroundSerial MRI and CSF biomarkers in normal aging, MCI, and AD
Vemuri, P., Wiste, H. J., Weigand, S. D., Knopman, D. S., Trojanowski, J. Q., Shaw, L. M., Bernstein, M. A., Aisen, P. S., Weiner, M., Petersen, R. C., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e7ca82 · Cited by 154
Reduced gray matter volume in normal adults with a maternal family history of Alzheimer disease
Honea, R. A., Swerdlow, R. H., Vidoni, E. D., Goodwin, J., & Burns, J. M. (2010) · Neurology · doi:10.1212/wnl.0b013e3181c918cb · Cited by 106 · cited 1×
“However, this observation of maternal transmission of the disease is consistent with earlier reports in the AD literature.(22,23) Of the AD patients, 66% were APOE ε4 carriers, and this confirms that APOE ε4 is a significant risk factor for AD (0 alleles: 34%; 1 allele: 47%; 2 alleles: 19%).”
ResultLocke, P. A., Conneally, P. M., Tanzi, R. E., Gusella, J. F., & Haines, J. L. (1995) · Genetic Epidemiology · doi:10.1002/gepi.1370120108 · Cited by 75 · cited 14×
“APOE ε4 is the single most significant risk factor identified to date for late-onset AD.29-31 Ito et al4 and others have shown that carriers of the APOE ε4 gene show faster disease progression, although this has not been replicated in all studies.”
BackgroundInfluential
Cited by
The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception
Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Liu, E., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.05.1769 · Cited by 1,010
Self-citationWeiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Cedarbaum, J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.11.001 · Cited by 348
“When 2-year follow-up cognitive data of healthy elderly subjects from the ADNI cohort were used to exclude participants with any indication of cognitive decline, significant atrophy in all ROIs was still found in the remaining “super-stable” cohort.”
MethodResultInfluentialSelf-citationRaghavan, N., Samtani, M. N., Farnum, M., Yang, E., Novak, G., Grundman, M., Narayan, V., DiBernardo, A., & Initiative, A. D. N. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.05.2187 · Cited by 96
Self-citationIto, K., Corrigan, B., Romero, K., Anziano, R., Neville, J., Stephenson, D., & Lalonde, R. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-130575 · Cited by 62
Metadata
- Authors
- Samtani, M. N., Farnum, M., Lobanov, V., Yang, E., Raghavan, N., DiBernardo, A., Narayan, V., & Initiative, A. T. A. D. N.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2012-05
- Volume
- 52
- Issue
- 5
- Pages
- 629-644
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W1969313677
- Cited by
- 80
- References
- 6
- FWCI
- 5.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An Improved Model for Disease Progression in Patients From the Alzheimer's Disease Neuroimaging Initiative. https://app.cochat.ai/papers/10.1177/0091270011405497
- The paper
- Samtani, M. N., Farnum, M., Lobanov, V., Yang, E., Raghavan, N., DiBernardo, A., Narayan, V., & Initiative, A. T. A. D. N. (2012). An Improved Model for Disease Progression in Patients From the Alzheimer's Disease Neuroimaging Initiative. The Journal of Clinical Pharmacology. https://doi.org/10.1177/0091270011405497
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.